Therapeutics (NON-Industry)

(F 04) Patient-Reported Benefits of Group-Based Online Mindfulness for Migraine: A Qualitative Study

(T 40) Ubrogepant Efficacy Based on Historical Cutaneous Allodynia and Triptan Response: Results from the PRODROME Trial

(T 41) Efficacy of Ubrogepant 100 mg Based on Prior Triptan Experience: Results From the ACHIEVE I Study

(T 42) Safety and Effectiveness of a Novel Implantable Neurostimulator for the Prevention of Resistant Migraine at 24 Months.

(T 45) A Review of the History and Pharmacology of Anti- Nausea Medications

(T 46) Efficacy and safety of rimegepant in the acute treatment of migraine among Chinese adults: real-world evidence from a multicenter, prospective, observational study

(T 47) Efficacy of rimegepant for acute migraine attacks presenting with dizziness or vertigo: a post-hoc analysis of a multicenter, prospective, real-world study

(T 48) Efficacy of CGRP-Targeted Gepants and Topiramate for Migraine Prevention: A Frequentist Meta-analysis

(T 49) Comparative Efficacy and Safety of CGRP Monoclonal Antibodies Versus Oral Gepants for Episodic Migraine Prevention: A Bayesian Network Meta-analysis of Randomized Controlled Trials

(T 50) Efficacy of Rimegepant in Patients with Vertigo: A Real-World Retrospective Study of Vestibular and Cochlear Outcomes

(T 51) Delayed remission in primary trigeminal neuralgia after microvascular decompression surgeries

(T 52) Efficacy of Combined Curcumin and Omega-3 Supplementation in the Management of Migraine: A Systematic Review of Randomized Controlled Trials

(T 53) Variability in Treatment Response Definitions Across Preventive Migraine

(T 54) Disease Course and Treatment Response of Visual Snow Syndrome : A Prospective Study in a Korean Population

(T 55) Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) Units for Headache Treatment in a United States Population.

(T 56) Digital Therapeutics and App-Based Behavioral Interventions for Migraine: A Systematic Review and Meta-Analysis of Clinical Outcomes

(T 57) Sleep Disorders in Primary Headache: A Systematic Review and Meta-Analysis of Prevalence, Bidirectional Relationships, and Sleep-Targeted Intervention Efficacy

(T 58) Occipital Nerve Block Efficacy in Neurocritical ICU (NICU) Patients with Acute Cephalgia

(T 59) Two-Step Sphenopalatine Ganglion Modulation Using Intranasal Lignocaine and High-Flow Oxygen for Acute Stroke-Associated Headache: A Prospective Case Series

(T 60) Patterns of Use and Impact of Over-the-Counter Rubs and Balms Among Persons with Migraine

(T 61) The impact of limited insurance coverage on the long-term persistence of CGRP monoclonal antibody therapy: A Multicenter, Real-World Study in Korea

(T 62) Real-world effectiveness and safety of CGRP monoclonal antibodies in elderly migraine patients: a Korean multicenter study

(T 63) Olanzapine in the Treatment of Status Migrainosus

(T 64) Trigeminal nerve blocks for medically intractable painful trigeminal neuropathy

(T 65) Amlodipine for Migraine Prevention

(T 66) Once-Nightly Pregabalin for Co-occurring Headaches, Nonrestorative Sleep, and Nightmares

(T 67) Title: Music Interventions for Migraine: A Scoping Review and Protocol

(T 68) Acute Treatment of Migraine with Rimegepant Improves Health-Related Quality of Life and Reduces Headache-Related Disability: Results from a Single-Arm, Prospective, Real-World Study

(T 69) Efficacy of Very Low Carbohydrate Diet on Glucose Dysregulation in Chronic Migraine

(T 71) Deficits in the Peripheral Sympathetic Nervous System Are Common in Patients with Migraine and Associate with Calcitonin-Gene Related Peptide (CGRP) Monoclonal Antibody (mAb) Treatment Response

(T 72) The safety of CGRP-targeted therapies in cerebrovascular disease

(T 73) The Association of Psychiatric Comorbidities with Preventive Medication Use in Patients with Migraine: a Cross-Institutional Electronic Health Record Analysis

(T 74) Physical Therapist-Delivered Biofeedback-Assisted Relaxation for Migraine: A Qualitative Analysis of Results from a Pilot Randomized Controlled Trial

(T 75) Predictors of response to biofeedback-assisted relaxation: an exploratory analysis

(T 76) Real-World Use of the Remote Electrical Neuromodulation (REN) Wearable for Migraine Management in Hawaii Demonstrates Positive Patient Outcomes: A Pilot Study

(T 77) Regional Patterns of Online Interest in Erenumab: A Comparative Study of the United States and Europe

(T 78) Patient Global Impression of Change Following Inpatient Treatment for Intractable Migraine

(T 79) Identifying and Targeting Potential Misrepresentation in Virtual Clinical Migraine Trials

(T 80) Effects of Spectral Modulation of White Light on Migraine Pain and Photophobia During Acute Attacks

(T 81) Digital Milestones and Public Interest in CGRP-Targeting Migraine Therapies: An Infodemiology Study in the United States

(T 82) Facilitators and Barriers to Eptinezumab Administration in Thailand: Preliminary Qualitative Findings from the FACEpi Study

(T 83) Real-World Longitudinal Outcomes of Acute Rimegepant in a Tertiary Migraine Population

(T 84) Efficacy of eptinezumab in patients refractory to CGRP targeted preventive treatments or onabotulinum toxin A for migraine: a retrospective cohort study

(T 86) The Evidence Gap for Non-OnabotulinumtoxinA in Migraine Prevention: A Systematic Review of Dosing, Efficacy, and Injection Techniques

(T 87) Prospective open-label pilot study of rimegepant as a treatment for cluster headache

(T 88) Olanzapine as a Bridge Therapy for Status Migranosus: A Retrospective Study of Dosing and Duration

(T 89) Efficacy and Tolerability of IV Dihydroergotamine in Treating Pediatric Headache in the Emergency Department: A Retrospective Review

(T 90) Efficacy of Neuromodulation Devices for Migraine Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials

(T 91) Patient-Reported Experiences with Dimethyltryptamine for Cluster Headache: An AI-Assisted Sentiment Analysis of Online Forums

(T 92) Symptom response to multiple epidural patches in patients with orthostatic headaches and no radiographic signs of spontaneous intracranial hypotension

(T 93) Efficacy and safety of calcitonin gene-related peptide (CGRP) monoclonal antibodies—erenumab, galcanezumab, and eptinezumab in episodic and chronic migraine.

(SA 02) Developing Research Partnerships to Support Recruitment and Engagement While Conducting a National Migraine Randomized Clinical Trial

(SA 04) Genetic Factors Associated With Ketamine Response Kinetics in Refractory Migraine